checkAd

    DGAP-Adhoc  555  0 Kommentare Biotest AG: Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share - Seite 2



    The information contained herein is not for distribution, directly or
    indirectly, in or into the United States of America and must not be
    distributed to U.S. persons (as defined in Regulation S of the U.S.
    Securities Act of 1933, as amended ('Securities Act')) or publications with
    a general circulation in the United States of America. This publication
    constitutes neither an offer to sell nor a solicitation to buy or subscribe
    to securities in the United States of America. The securities have not been
    and will not be registered under the Securities Act and may not be offered
    or sold in the United States of America absent registration or an exemption
    from registration under the Securities Act. The Issuer does not intend to
    register any portion of the offering in the United States of America or to
    conduct a public offering of the securities in the United States of
    America.

    No prospectus has been or will be approved for publication in the United
    Kingdom in respect of the securities to which this publication relates.
    Consequently, this publication is being distributed only to, and is
    directed only at, Qualified Investors (as defined below) who (i) are
    persons who have professional experience in matters relating to investments
    falling within Article 19(5) of the Financial Services and Markets Act 2000
    (Financial Promotion) Order 2005, as amended (the 'Order'), (ii) are high
    net worth entities falling within Articles 49(a) to (d) of the Order, or
    (iii) other persons to whom it may otherwise lawfully be communicated (all
    such persons together being referred to as 'relevant persons').
    Furthermore, this publication is only addressed to and directed at persons
    in member states of the European Economic Area (other than in Germany) who
    are 'qualified investors' within the meaning of Article 2(1)(e) of the
    Prospectus Directive (Directive 2003/71/EC as amended) ('Qualified
    Investors'). Any investment or investment activity to which this
    publication relates is only available to and will only be engaged in with
    (i) in the United Kingdom, relevant persons who are also Qualified
    Investors, and (ii) in any other member state of the European Economic Area
    (other than in Germany and Luxembourg), Qualified Investors. Any other
    persons who receive this publication in the European Economic Area (other
    than in Germany or Luxembourg) should not rely on or act upon it.

    The information contained herein is not for publication or distribution,
    directly or indirectly, in or into the United States of America, Canada,
    Japan or Australia.

    Disclaimer
    Seite 2 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen

    Verfasst von EQS Group AG
    DGAP-Adhoc Biotest AG: Biotest AG sets the subscription price and the offer price for the new preferred shares at EUR 52.00 per preferred share - Seite 2 Biotest AG / Key word(s): Capital Increase 10.06.2013 19:05 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this …

    Schreibe Deinen Kommentar

    Disclaimer